Peptide library
BPC-157
Not FDA-approved
Early human evidence
Policy context
The October 30, 2026 Federal Register notice announces draft interim guidance for certain peptide bulk substances under section 503A. Draft guidance is nonbinding; it is not drug approval, a permanent 503A bulks-list decision or a section 503B pathway. HHS may reconsider enforcement policy as safety or quality information changes.[2][4]
FDA retains safety concerns in its withdrawn-nomination records for BPC-157, CJC-1295, injectable GHK-Cu, ipamorelin acetate and thymosin beta-4 fragment. Withdrawal of a nomination is not a safety clearance. Ipamorelin acetate also appears in the separate 503B category 2 record. Route-specific uncertainty and limited human data still matter.[5]
| Preparation | Route |
|---|---|
| BPC-157 acetate | subcutaneous, intramuscular, oral, topical |
Evidence record
- Product and route
- The pilot used an intravenous route; this is not an instruction for use.
- Approval scope
- No FDA-approved BPC-157 product is established in the reviewed official evidence.
- Mechanism
- This evidence does not establish a human therapeutic mechanism.
- Evidence
- A very small, uncontrolled human pilot has been published.
- Limits
- That observation cannot establish injury repair or long-term safety.
- Safety context
- FDA considers clinical safety information insufficient.
A reading exercise
Choose one personal account on a page mentioning BPC-157 and separate the storyteller's experience from the conclusion the page draws. Write down what would need to be recorded for another reader to examine that conclusion: the question, the observation method, and the time covered. Then imagine an account that disagrees. Would the page's proposed explanation have room for both, or has it supplied no way to distinguish them? This exercise does not require denying anyone's experience. It asks what additional observations and comparison rules would turn a memorable account into a claim that could be checked again.
Questions to take away
- Which part describes the person's experience, and which part is the page's broader conclusion?
- What would another observer need to record to examine that conclusion consistently?
- How would the proposed explanation handle an account reporting a different experience?
Sources
Each date identifies a source check. It is separate from this page’s publication date.
- Lee — PubMed; checked
- FDA BPC-157 — FDA; checked